MDM2 and melanoma: Regarding the small molecule inhibitor of MDM2 alrizomadlin (APG-115) in combination with pembrolizumab for the treatment of unresectable/metastatic solid tumors that have progressed on immunotherapy in adults or children (NCT03611868), preliminary and interim findings from 6 cohorts encompassing 130 patients reveal the following outcomes: a 13% overall response rate in melanoma, with 2 complete responses and 3 partial responses among 38 patients with assessable efficacy.